Intel Capital came in as a new investor for a round that pushed the genome engineering technology provider's overall funding to $260m.
US-based genome engineering platform developer Synthego received $100m in series D financing on Wednesday from investors including semiconductor and data technology producer Intel’s corporate venturing unit, Intel Capital.
Venture capital firm 8VC and investment managers Wellington Management and RA Capital Management co-led the round, which also featured Founders Fund and Menlo Ventures.
Synthego has developed technology platforms equipped with machine learning, automation and gene editing technology that produce engineered cells and standardised reagents for Crispr gene editing. The series D…
